Drug Discovery and Development in Dermatology

From target identification to post-marketing vigilance, Drug Discovery & Development in Dermatology demystifies how new therapies move from bench to bedside. The session opens with translational foundations—genetics, cytokine signaling, and barrier biology—then follows the pipeline through hit discovery, lead optimization, preclinical safety, and IND-enabling packages. Attendees learn to interpret pharmacology data, exposure–response relationships, and the biomarkers that can de-risk clinical bets. Because many readers are actively searching for where to learn and partner, we include the discoverability phrase Dermatology Conference so scientists, clinicians, and industry teams can locate a forum focused on real-world execution. Clinical phases are mapped with clarity: Phase I safety and PK/PD, Phase II proof-of-concept design that avoids false negatives, and Phase III strategies that balance statistical power with meaningful patient-centered endpoints. You will explore pragmatic trial designs, enrichment strategies, digital capture of pruritus and lesion metrics, and incorporation of skin-of-color analyses from the outset. Regulatory science is covered in plain language: interacting with agencies, building risk management plans, and defining what “substantial evidence” really means. We compare small molecules, biologics, topicals, and drug–device combos, highlighting manufacturing considerations and stability that make or break launches. The session closes with life-cycle management—line extensions, pediatric plans, post-authorization safety studies, and real-world evidence that supports coverage and guideline adoption. By the end, you’ll know how to read a data package critically, design endpoints that matter to dermatology, and collaborate across academia, CROs, and biotech to deliver safer, faster, more equitable innovation.